Medical Specialty >> Oncology
Severe COVID for People Under 45: Who’s Most at Risk?
4:49 PM CDT.
By Steven Reinberg HealthDay Reporter Read article
- Screening Often Misses Endometrial Cancer in Black Women
- Long Distance to Care Can Mean Worse Outcomes for Young Cancer Patients
- FDA Approves First Lymphoma Drug for Dogs
- Alcohol Tied to 740,000 Cancer Cases Worldwide in 2020
JOURNAL UPDATE
Inequalities Found With U.S. Family and Medical Leave Act Requirement
4:12 PM CDT.Women disproportionately excluded in minimum hours requirement; tenure requirement excludes Blacks,…
- VTE Risk Up for Children With Inflammatory Bowel Disease
- Smoking Cessation After NSCLC Diagnosis Cuts Mortality Risk
- Survival Up for Multiple Cancer Types for Teens, Young Adults
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - Hematology & Oncology
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
